1. Biomimetic design of bioartificial scaffolds for the in vitro modelling of human cardiac fibrosis
- Author
-
Mattia Spedicati, Gerardina Ruocco, Alice Zoso, Leonardo Mortati, Andrea Lapini, Andrea Delledonne, Carla Divieto, Veronica Romano, Clotilde Castaldo, Franca Di Meglio, Daria Nurzynska, Irene Carmagnola, and Valeria Chiono
- Subjects
bioartificial scaffold ,cardiac fibrosis ,in vitro model ,poly(caprolactone) ,gelatin ,extracellular matrix ,Biotechnology ,TP248.13-248.65 - Abstract
In vitro models of pathological cardiac tissue have attracted interest as predictive platforms for preclinical validation of therapies. However, models reproducing specific pathological features, such as cardiac fibrosis size (i.e., thickness and width) and stage of development are missing. This research was aimed at engineering 2D and 3D models of early-stage post-infarct fibrotic tissue (i.e., characterized by non-aligned tissue organization) on bioartificial scaffolds with biomimetic composition, design, and surface stiffness. 2D scaffolds with random nanofibrous structure and 3D scaffolds with 150 µm square-meshed architecture were fabricated from polycaprolactone, surface-grafted with gelatin by mussel-inspired approach and coated with cardiac extracellular matrix (ECM) by 3 weeks culture of human cardiac fibroblasts. Scaffold physicochemical properties were thoroughly investigated. AFM analysis of scaffolds in wet state, before cell culture, confirmed their close surface stiffness to human cardiac fibrotic tissue. Following 3 weeks culture, biomimetic biophysical and biochemical scaffold properties triggered the activation of myofibroblast phenotype. Upon decellularization, immunostaining, SEM and two-photon excitation fluorescence microscopy showed homogeneous decoration of both 2D and 3D scaffolds with cardiac ECM. The versatility of the approach was demonstrated by culturing ventricular or atrial cardiac fibroblasts on scaffolds, thus suggesting the possibility to use the same scaffold platforms to model both ventricular and atrial cardiac fibrosis. In the future, herein developed in vitro models of cardiac fibrotic tissue, reproducing specific pathological features, will be exploited for a fine preclinical tuning of therapies.
- Published
- 2022
- Full Text
- View/download PDF